Incidentaloma differential diagnosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(12 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Incidentaloma}}
[[Image:Home_logo1.png|right|250px|link=https://www.wikidoc.org/index.php/Incidentaloma]]
{{CMG}}; {{AE}} {{MAD}}  
{{CMG}}; {{AE}} {{MAD}}  


==Overview==
==Overview==
[[Adrenal gland|Adrenal]] incidentaloma must be differentiated from other diseases that cause adrenal masses such as adrenal [[adenoma]], [[adrenocortical carcinoma]], [[Cushing's syndrome]], [[pheochromocytoma]], and [[metastasis]].
[[Adrenal gland|Adrenal]] incidentaloma must be differentiated from other diseases that cause [[Adrenal gland|adrenal]] masses such as [[Adrenal gland|adrenal]] [[adenoma]], [[adrenocortical carcinoma]], [[Cushing's syndrome]], [[pheochromocytoma]], [[metastasis]], and other causes of bilateral adrenal masses.
 
==Differentiating different causese of Incidentaloma==
 
*The cause of adrenal incidentaloma commonly include [[adrenal adenoma]], sub-clinical [[Cushing's syndrome]], [[pheochromocytoma]], and [[adrenocortical carcinoma]]. These causes can be differentiated from each other as follows:


==Differentiating Incidentaloma from other Diseases==
*[[Adrenal gland|Adrenal]] incidentaloma must be differentiated from other diseases that cause adrenal masses such as adrenal [[adenoma]], [[adrenocortical carcinoma]], [[Cushing's syndrome]], [[pheochromocytoma]], and [[metastasis]].
{| style="border: 0px; font-size: 90%; margin: 3px; width: 1000px" align="center"
{| style="border: 0px; font-size: 90%; margin: 3px; width: 1000px" align="center"


|+
|+
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Differential Diagnosis}}
! style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Differential Diagnosis}}
! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|Clinical picture}}
! style="background: #4479BA; width: 300px;" |{{fontcolor|#FFF|Clinical picture}}
! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|Imagings}}
! style="background: #4479BA; width: 300px;" |{{fontcolor|#FFF|Imagings}}
! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|Laboratory tests}}
! style="background: #4479BA; width: 300px;" |{{fontcolor|#FFF|Laboratory tests}}
|-
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[Adrenal adenoma]]
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[Adrenal adenoma]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
**Symptoms related to excess [[glucocorticoid]]
**Symptoms related to excess [[glucocorticoid]]
**Symptoms related to excess [[mineralocorticoid]]
**Symptoms related to excess [[mineralocorticoid]]
|
| style="padding: 5px 5px; background: #F5F5F5;" |


* Round and homogeneous density, smooth contour and sharp margination
*Round and homogeneous density, smooth contour and sharp margination
* Diameter less than 4 cm, unilateral location
*Diameter less than 4 cm, unilateral location
* Low unenhanced [[Computed tomography|CT]] attenuation values (<10 HU)
*Low unenhanced [[Computed tomography|CT]] attenuation values (<10 HU)
* Rapid [[contrast medium]] washout (10 minutes after administration of contrast, an absolute [[contrast medium]] washout of more than 50 percent)
*Rapid [[contrast medium]] washout (10 minutes after administration of contrast, an absolute [[contrast medium]] washout of more than 50 percent)
* Isointensity with [[liver]] on both T1 and T2 weighted [[Magnetic resonance imaging|MRI]] sequences
*Isointensity with [[liver]] on both T1 and T2 weighted [[Magnetic resonance imaging|MRI]] sequences
* [[Chemical shift]]: evidence of [[lipid]] on [[Magnetic resonance imaging|MRI]]
*[[Chemical shift]]: evidence of [[lipid]] on [[Magnetic resonance imaging|MRI]]
|
| style="padding: 5px 5px; background: #F5F5F5;" |


* [[Cortisol level]]
*[[Cortisol level]]
* Fasting serum [[cortisol]] at 8 AM following a 1 mg dose of [[dexamethasone]] at bedtime
*Fasting serum [[cortisol]] at 8 AM following a 1 mg dose of [[dexamethasone]] at bedtime
* [[Renin]] (PRA) or plasma renin concentration (PRC): very low in patients with primary aldosteronism, usually less than 1 ng/mL per hour for PRA and usually undetectable for PRC<ref />
*[[Renin]] (PRA) or plasma [[renin]] concentration (PRC): Very low in patients with [[Hyperaldosteronism|primary aldosteronism,]] usually less than 1 ng/mL per hour for PRA and usually undetectable for PRC<ref />
|-
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[Adrenocortical carcinoma|'''Adrenocortica'''l carcinoma]]
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[Adrenocortical carcinoma|'''Adrenocortica'''l carcinoma]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Mass effect symptoms
*Mass effect symptoms
* Symptoms related to  excess [[glucocorticoid]]
*Symptoms related to  excess [[glucocorticoid]]
* Symptoms related to  excess [[mineralocorticoid]]
*Symptoms related to  excess [[mineralocorticoid]]
* Symptoms related to  excess [[androgen]] or [[estrogen]] secretion
*Symptoms related to  excess [[androgen]] or [[estrogen]] secretion
|
| style="padding: 5px 5px; background: #F5F5F5;" |
*Irregular shape
*Irregular shape
*Inhomogeneous density because of central areas of low attenuation due to [[tumor]] [[necrosis]]
*Inhomogeneous density because of central areas of low attenuation due to [[tumor]] [[necrosis]]
*[[Tumor]] [[calcification]]
*[[Tumor]] [[calcification]]
*Diameter usually >4 cm
*Diameter usually > 4 cm
*Unilateral location
*Unilateral location
*High unenhanced [[Computed tomography|CT]] attenuation values (>20 HU)
*High unenhanced [[Computed tomography|CT]] attenuation values (>20 HU)
Line 52: Line 54:
*High standardized uptake value (SUV) on FDG-[[PET scan|PET-CT]] study
*High standardized uptake value (SUV) on FDG-[[PET scan|PET-CT]] study
*Evidence of local invasion or [[Metastasis|metastases]]
*Evidence of local invasion or [[Metastasis|metastases]]
|
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Androgen|Adrenal androgens]] [[[DHEAS]]]
*[[Androgen|Adrenal androgens]] ([[Dehydroepiandrosterone|DHEAS]])
* [[Androstenedione]]
*[[Androstenedione]]
* Bioavailable [[testosterone]] should be measured in every patient.
*Bioavailable [[testosterone]] should be measured in every patient.
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]]
*[[17-Hydroxyprogesterone|17-hydroxyprogesterone]]
* Serum [[estradiol]] in men and postmenopausal women
*Serum [[estradiol]] in men and post-menopausal women
* [[Cortisol level]]
*[[Cortisol level]]
* Fasting serum [[cortisol]] at 8 AM following a 1 mg dose of [[dexamethasone]] at bedtime
*Fasting serum [[cortisol]] at 8 AM following a 1 mg dose of [[dexamethasone]] at bedtime
|-
|-
|'''[[Cushing's syndrome]]'''
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Cushing's syndrome]]'''
|
| style="padding: 5px 5px; background: #F5F5F5;" |
* Rapid [[Obesity|weight gain]], particularly of the [[trunk]] and [[face]] with [[limbs]] sparing ([[central obesity]])
*Rapid [[Obesity|weight gain]], particularly of the [[trunk]] and [[face]] with [[limbs]] sparing ([[central obesity]])
* Proximal [[muscle weakness]]
*Proximal [[muscle weakness]]
* A [[round face]] often referred to as a "[[moon face]]"
*A [[round face]] often referred to as a "[[moon face]]"
* Excess [[sweating]]
*Excess [[sweating]]
* [[Headache]]
*[[Headache]]
|
| style="padding: 5px 5px; background: #F5F5F5;" |
* Imaging may show [[mass]] if presents
*Imaging may show [[mass]] if presents
|
| style="padding: 5px 5px; background: #F5F5F5;" |
* 24-hour urine [[cortisol]]
*24-hour urine [[cortisol]]
* Midnight salivary [[cortisol]]
*Mid-night salivary [[cortisol]]
* Low dose [[dexamethasone]] suppression test; high [[cortisol]] level after the [[dexamethasone]] test is suggestive of [[hypercortisolism]].
*Low dose [[dexamethasone]] suppression test; high [[cortisol]] level after the [[dexamethasone]] test is suggestive of [[hypercortisolism]].
|-
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[Pheochromocytoma]]
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[Pheochromocytoma]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Palpitations]] especially in epinephrine producing tumors.<sup>[[Pheochromocytoma history and symptoms#cite note-pmid8325290-3|[3]]]</sup>
*[[Palpitations]] especially in epinephrine producing tumors.<sup>[[Pheochromocytoma history and symptoms#cite note-pmid8325290-3|[3]]]</sup>
* [[Anxiety]] often resembling that of a [[panic attack]]
*[[Anxiety]] often resembling that of a [[panic attack]]
* [[Sweating]]
*[[Sweating]]
* [[Headaches]] occurs in 90 % of patients.
*[[Headaches]] occurs in 90 % of patients.
* Paroxysmal attacks of [[hypertension]] but some patients have normal [[blood pressure]].
*Paroxysmal attacks of [[hypertension]] but some patients have normal [[blood pressure]].
* It may be [[asymptomatic]] and discovered incidentally after [[Screening (medicine)|screening]] for [[MEN, type 2|MEN]] patients.
*It may be [[asymptomatic]] and discovered incidentally after [[Screening (medicine)|screening]] for [[MEN, type 2|MEN]] patients.
|[null Insert paragraph]
| style="padding: 5px 5px; background: #F5F5F5;" |
* Increased attenuation on nonenhanced [[Computed tomography|CT]] (>20 HU)
*Increased attenuation on nonenhanced [[Computed tomography|CT]] ( > 20 HU)
* Increased [[mass]] vascularity
*Increased [[mass]] vascularity
* Delay in [[contrast medium]] washout (10 minutes after administration of contrast, an absolute [[contrast medium]] washout of less than 50 percent)
*Delay in [[contrast medium]] washout (10 minutes after administration of contrast, an absolute [[contrast medium]] washout of less than 50 percent)
* High signal intensity on T2 weighted [[Magnetic resonance imaging|MRI]]
*High signal intensity on T2 weighted [[Magnetic resonance imaging|MRI]]
* Cystic and [[hemorrhagic]] changes
*Cystic and [[hemorrhagic]] changes
* Variable size and may be bilateral
*Variable size and may be bilateral
|
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Plasma]] fractionated [[Metanephrine|metanephrines]] 
*[[Plasma]] fractionated [[Metanephrine|metanephrines]] 
* 24-hour [[urinary]] fractionated [[Metanephrine|metanephrines]]
*24-hour [[urinary]] fractionated [[Metanephrine|metanephrines]]
|-
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[Adrenal metastases|Adrenal metastasis]]
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[Adrenal metastases|Adrenal metastasis]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Symptoms and signs of primary [[malignancy]] especially [[lung cancer]]
*Symptoms and signs of primary [[malignancy]] especially [[lung cancer]]
* General constitutional symptoms:
*General constitutional symptoms:
** [[Fever]]
**[[Fever]]
** [[Fatigue]]
**[[Fatigue]]
** [[Weight loss]]
**[[Weight loss]]
|
| style="padding: 5px 5px; background: #F5F5F5;" |
**Irregular shape and inhomogeneous nature
**Irregular shape and inhomogeneous nature
**Tendency to be bilateral
**Tendency to be bilateral
**High unenhanced [[Computed tomography|CT]] attenuation values (>20 HU) and enhancement with [[Contrast medium|intravenous contrast]] on [[Computed tomography|CT]]
**High unenhanced [[Computed tomography|CT]] attenuation values ( > 20 HU) and enhancement with [[Contrast medium|intravenous contrast]] on [[Computed tomography|CT]]
**Delay in [[contrast medium]] washout (10 minutes after administration of contrast, an absolute [[contrast medium]] washout of less than 50 percent)
**Delay in [[contrast medium]] washout (10 minutes after administration of contrast, an absolute [[contrast medium]] washout of less than 50 percent)
**Isointensity or slightly less intense than the liver on T1 weighted [[Magnetic resonance imaging|MRI]] and high to intermediate signal intensity on T2 weighted [[Magnetic resonance imaging|MRI]] (representing an increased water content)
**Iso-intensity or slightly less intense than the liver on T1 weighted [[Magnetic resonance imaging|MRI]] and high to intermediate signal intensity on T2 weighted [[Magnetic resonance imaging|MRI]] (representing an increased water content)
**Elevated standardized uptake value on FDG-[[PET scan]]
**Elevated standardized uptake value on FDG-[[PET scan]]
| style="padding: 5px 5px; background: #F5F5F5;" |
|
|
|}
|}


== Differential diagnosis of Cushing's disease from other diseases ==
===Differential diagnosis of Cushing's disease from other diseases===
The table below summarizes the findings that differentiate Cushing's disease from other conditions that may cause [[Hypertension|hypertensio]]<nowiki/>n, [[hyperandrogenism]], and [[obesity]]. Facial [[plethora]], [[skin changes]], [[osteoporosis]], [[nephrolithiasis]] and [[neuropsychiatric]] conditions should raise the concern for Cushing's syndrome.<ref name="pmid11253984">{{cite journal |vauthors=Boscaro M, Barzon L, Fallo F, Sonino N |title=Cushing's syndrome |journal=Lancet |volume=357 |issue=9258 |pages=783–91 |year=2001 |pmid=11253984 |doi=10.1016/S0140-6736(00)04172-6 |url=}}</ref><ref name="pmid11571938">{{cite journal |vauthors=Findling JW, Raff H |title=Diagnosis and differential diagnosis of Cushing's syndrome |journal=Endocrinol. Metab. Clin. North Am. |volume=30 |issue=3 |pages=729–47 |year=2001 |pmid=11571938 |doi= |url=}}</ref><ref name="pmid9793762">{{cite journal |vauthors=Newell-Price J, Trainer P, Besser M, Grossman A |title=The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states |journal=Endocr. Rev. |volume=19 |issue=5 |pages=647–72 |year=1998 |pmid=9793762 |doi=10.1210/edrv.19.5.0346 |url=}}</ref><ref name="urlHow Is Metabolic Syndrome Diagnosed? - NHLBI, NIH">{{cite web |url=https://www.nhlbi.nih.gov/health/health-topics/topics/ms/diagnosis |title=How Is Metabolic Syndrome Diagnosed? - NHLBI, NIH |format= |work= |accessdate=}}</ref>
The table below summarizes the findings that differentiate [[Cushing's disease]] from other conditions that may cause [[Hypertension|hypertensio]]<nowiki/>n, [[hyperandrogenism]], and [[obesity]]. Facial [[plethora]], [[skin changes]], [[osteoporosis]], [[nephrolithiasis]] and [[neuropsychiatric]] conditions should raise the concern for [[Cushing's syndrome]].<ref name="pmid11253984">{{cite journal |vauthors=Boscaro M, Barzon L, Fallo F, Sonino N |title=Cushing's syndrome |journal=Lancet |volume=357 |issue=9258 |pages=783–91 |year=2001 |pmid=11253984 |doi=10.1016/S0140-6736(00)04172-6 |url=}}</ref><ref name="pmid11571938">{{cite journal |vauthors=Findling JW, Raff H |title=Diagnosis and differential diagnosis of Cushing's syndrome |journal=Endocrinol. Metab. Clin. North Am. |volume=30 |issue=3 |pages=729–47 |year=2001 |pmid=11571938 |doi= |url=}}</ref><ref name="pmid9793762">{{cite journal |vauthors=Newell-Price J, Trainer P, Besser M, Grossman A |title=The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states |journal=Endocr. Rev. |volume=19 |issue=5 |pages=647–72 |year=1998 |pmid=9793762 |doi=10.1210/edrv.19.5.0346 |url=}}</ref><ref name="urlHow Is Metabolic Syndrome Diagnosed? - NHLBI, NIH">{{cite web |url=https://www.nhlbi.nih.gov/health/health-topics/topics/ms/diagnosis |title=How Is Metabolic Syndrome Diagnosed? - NHLBI, NIH |format= |work= |accessdate=}}</ref>
<br>
<br>
{| align="center"
{| align="center"
Line 118: Line 121:
|
|
{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
! style="background:#4479BA; color: #FFFFFF;" | Conditions
! style="background:#4479BA; color: #FFFFFF;" |Conditions
! style="background:#4479BA; color: #FFFFFF;" |Causes
! style="background:#4479BA; color: #FFFFFF;" |Causes
! style="background:#4479BA; color: #FFFFFF;" |Associated features
! style="background:#4479BA; color: #FFFFFF;" |Associated features
! style="background:#4479BA; color: #FFFFFF;" |Diagnostic approach  
! style="background:#4479BA; color: #FFFFFF;" |Diagnostic approach


|-
|-
Line 132: Line 135:
*[[Ectopic ACTH Syndrome|Ectopic ACTH secretion]]
*[[Ectopic ACTH Syndrome|Ectopic ACTH secretion]]
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* [[Obesity]]
*[[Obesity]]
*[[Hypertension]]
*[[Hypertension]]
*[[PCOS]]/[[hyperandrogenism]]
*[[PCOS]]/[[hyperandrogenism]]
*[[Oligomenorrhea]]/[[hypogonadism]]
*[[Oligomenorrhea]]/[[hypogonadism]]
*[[Osteoporosis]]
*[[Osteoporosis]]
*[[Myopathy]]/cutaneous wasting
*[[Myopathy]]/cutaneous wasting
*[[Neuropsychiatric]] problems
*[[Neuropsychiatric]] problems
*[[Kidney stone|Kidney stones]]
*[[Kidney stone|Kidney stones]]
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
*24-hour urine cortisol
*24-hour urine [[cortisol]]
*Midnight salivary cortisol
*Midnight salivary [[cortisol]]
*[[Dexamethasone Oral|Low dose dexamethasone]] challenge test
*[[Dexamethasone Oral|Low dose dexamethasone]] challenge test
*[[CRH]] stimulation
*[[CRH]] stimulation
*[[Dexamethasone Oral|High dose dexamethasone]] test
*[[Dexamethasone Oral|High dose dexamethasone]] test
*[[MRI|MRI brain]]
*[[MRI|MRI brain]]
*CT/MRI adrenals
*[[Computed tomography|CT]]/[[Magnetic resonance imaging|MRI]] adrenals


|-
|-
Line 158: Line 161:
*[[HIV]]
*[[HIV]]
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* [[Obesity]]
*[[Obesity]]
*[[Hypertension]]
*[[Hypertension]]
*[[PCOS]]/[[hyperandrogenism]]
*[[PCOS]]/[[hyperandrogenism]]
*[[Oligomenorrhea]]/[[hypogonadism]]
*[[Oligomenorrhea]]/[[hypogonadism]]
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
*Urinary free cortisol
*[[Urinary system|Urinary]] free [[cortisol]]
*Midnight salivary cortisol
*Midnight salivary [[cortisol]]
*Low dose dexamethasone challenge test
*Low dose [[dexamethasone]] challenge test
*[[Glucose tolerance test]]
*[[Glucose tolerance test]]
*Loperamide test
*[[Loperamide]] test
|-
|-
| style="background:#DCDCDC;" align="center" |[[Metabolic syndrome X]]
| style="background:#DCDCDC;" align="center" |[[Metabolic syndrome X]]
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
*Familial/genetic
*[[Family|Familial]]/[[Genetics|genetic]]
*Obesity
*[[Obesity]]
*Insulin resistance
*[[Insulin]] resistance
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* [[Obesity]]
*[[Obesity]]
*[[Hypertension]]
*[[Hypertension]]
*[[PCOS]]/[[hyperandrogenism]]
*[[PCOS]]/[[hyperandrogenism]]
Line 190: Line 193:
|}
|}


== Differentiating pheochromocytoma from other diseases ==
===Differentiating pheochromocytoma from other diseases===
Pheochromocytoma must be differentiated from other causes of [[paroxysmal hypertension]]. The differentials include:
Pheochromocytoma must be differentiated from other causes of [[paroxysmal hypertension]]. The differentials include:
{| class="wikitable"
{| class="wikitable"
Line 198: Line 201:
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Investigations
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Investigations
|-
|-
|Pheochromocytoma
| style="background:#DCDCDC;" align="center" |[[Pheochromocytoma]]
|The symptoms of a pheochromocytoma are those of [[sympathetic nervous system]]<nowiki/>hyperactivity and include:<sup>[[Renal artery stenosis ultrasound#cite note-pmid23457117-1|[1]]]</sup>
|The symptoms of a [[pheochromocytoma]] are those of [[sympathetic nervous system]]<nowiki/>hyperactivity and include:<sup>[[Renal artery stenosis ultrasound#cite note-pmid23457117-1|[1]]]</sup>
* [[Palpitations]] (especially in [[epinephrine]] producing tumors)
 
* [[Anxiety]] 
*[[Palpitations]] (especially in [[epinephrine]] producing tumors)
* [[Sweating]]
*[[Anxiety]] 
* [[Headaches]] (90 % of patients)
*[[Sweating]]
* Paroxysmal attacks of [[hypertension]]
*[[Headaches]] (90 % of patients)
* May be asymptomatic (incidentally discovered in [[Multiple endocrine neoplasia|MEN]] syndrome patients)
*Paroxysmal attacks of [[hypertension]]
*May be asymptomatic (incidentally discovered in [[Multiple endocrine neoplasia|MEN]] syndrome patients)
|
|
* [[Tachycardia]]
*[[Tachycardia]]
* [[Hypertension]], including paroxysmal (sporadic, episodic) high [[blood pressure]], which sometimes can be more difficult to detect.
*[[Hypertension]], including paroxysmal (sporadic, episodic) high [[blood pressure]], which sometimes can be more difficult to detect.
* [[Orthostatic hypotension]]
*[[Orthostatic hypotension]]
|
|
* '''High-risk patients''':  
*'''High-risk patients''':  
** [[Plasma]] fractionated [[Metanephrine|metanephrines]]  
**[[Plasma]] fractionated [[Metanephrine|metanephrines]]
** 24-hour [[urinary]] fractionated [[Metanephrine|metanephrines]], catecholamines
**24-hour [[urinary]] fractionated [[Metanephrine|metanephrines]], [[Catecholamine|catecholamines]]
** Imaging studies ([[CT scan]], [[Magnetic resonance imaging|MRI]] and  iodine-123-meta-iodobenzylguanidine or MIBG scintiscan)<sup>[[Renal artery stenosis ultrasound#cite note-pmid23457117-1|[1]]]</sup>
**Imaging studies ([[CT scan]], [[Magnetic resonance imaging|MRI]] and  iodine-123-meta-iodobenzylguanidine or MIBG scintiscan)<sup>[[Renal artery stenosis ultrasound#cite note-pmid23457117-1|[1]]]</sup>


* '''Low-risk patients''':  
*'''Low-risk patients''':  
** 24-hour [[urinary]] fractionated [[catecholamines]] and [[Metanephrine|metanephrines]]<sup>[[Pheochromocytoma laboratory findings#cite note-pmid12574179-4|[4]]]</sup>
**24-hour [[urinary]] fractionated [[catecholamines]] and [[Metanephrine|metanephrines]]<sup>[[Pheochromocytoma laboratory findings#cite note-pmid12574179-4|[4]]]</sup>
|-
|-
|Pseudopheochromocytoma (idiopathic)<ref name="pmid102187452">{{cite journal| author=Mann SJ| title=Severe paroxysmal hypertension (pseudopheochromocytoma): understanding the cause and treatment. | journal=Arch Intern Med | year= 1999 | volume= 159 | issue= 7 | pages= 670-4 | pmid=10218745 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10218745  }}</ref><ref name="pmid10218745">{{cite journal| author=Mann SJ| title=Severe paroxysmal hypertension (pseudopheochromocytoma): understanding the cause and treatment. | journal=Arch Intern Med | year= 1999 | volume= 159 | issue= 7 | pages= 670-4 | pmid=10218745 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10218745  }}</ref><ref name="pmid8824124">{{cite journal| author=Mann SJ| title=Severe paroxysmal hypertension. An automatic syndrome and its relationship to repressed emotions. | journal=Psychosomatics | year= 1996 | volume= 37 | issue= 5 | pages= 444-50 | pmid=8824124 | doi=10.1016/S0033-3182(96)71532-3 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8824124  }}</ref><ref name="pmid17921824">{{cite journal| author=Sharabi Y, Goldstein DS, Bentho O, Saleem A, Pechnik S, Geraci MF et al.| title=Sympathoadrenal function in patients with paroxysmal hypertension: pseudopheochromocytoma. | journal=J Hypertens | year= 2007 | volume= 25 | issue= 11 | pages= 2286-95 | pmid=17921824 | doi=10.1097/HJH.0b013e3282ef5fac | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17921824  }}</ref>  
| style="background:#DCDCDC;" align="center" |Pseudopheochromocytoma (idiopathic)<ref name="pmid102187452">{{cite journal| author=Mann SJ| title=Severe paroxysmal hypertension (pseudopheochromocytoma): understanding the cause and treatment. | journal=Arch Intern Med | year= 1999 | volume= 159 | issue= 7 | pages= 670-4 | pmid=10218745 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10218745  }}</ref><ref name="pmid10218745">{{cite journal| author=Mann SJ| title=Severe paroxysmal hypertension (pseudopheochromocytoma): understanding the cause and treatment. | journal=Arch Intern Med | year= 1999 | volume= 159 | issue= 7 | pages= 670-4 | pmid=10218745 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10218745  }}</ref><ref name="pmid8824124">{{cite journal| author=Mann SJ| title=Severe paroxysmal hypertension. An automatic syndrome and its relationship to repressed emotions. | journal=Psychosomatics | year= 1996 | volume= 37 | issue= 5 | pages= 444-50 | pmid=8824124 | doi=10.1016/S0033-3182(96)71532-3 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8824124  }}</ref><ref name="pmid17921824">{{cite journal| author=Sharabi Y, Goldstein DS, Bentho O, Saleem A, Pechnik S, Geraci MF et al.| title=Sympathoadrenal function in patients with paroxysmal hypertension: pseudopheochromocytoma. | journal=J Hypertens | year= 2007 | volume= 25 | issue= 11 | pages= 2286-95 | pmid=17921824 | doi=10.1097/HJH.0b013e3282ef5fac | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17921824  }}</ref>
|Paroxysmal activation of the [[Sympathetic nervous system|sympathetic system]] causing:
|Paroxysmal activation of the [[Sympathetic nervous system|sympathetic system]] causing:
* Emotional distress
 
* Acute onset of high [[blood pressure]]  
*Emotional distress
* [[Headache]]
*Acute onset of high [[blood pressure]]
* [[Chest pain]]
*[[Headache]]
* [[Nausea]]
*[[Chest pain]]
* [[Palpitation|Palpitations]]
*[[Nausea]]
* [[Flushing]]
*[[Palpitation|Palpitations]]
* Duration of attacks ranges from minutes to hours
*[[Flushing]]
* Physical symptoms occur before feeling fear
*Duration of attacks ranges from minutes to hours
*Physical symptoms occur before feeling fear


|
|
* [[Hypertension]]
*[[Hypertension]]
* [[Tachycardia]]
*[[Tachycardia]]
|
|
* Increase in plasma [[catecholamines]] between and during attacks.
*Increase in plasma [[catecholamines]] between and during attacks.
|-
|-
|[[Panic attacks]]
| style="background:#DCDCDC;" align="center" |[[Panic attacks]]
|
|
* Paroxysms of increased [[Sympathetic nervous system|sympathetic activity]]
*Paroxysms of increased [[Sympathetic nervous system|sympathetic activity]]
* Episodes of fear or [[panic attacks]]
*Episodes of fear or [[panic attacks]]
* [[Chest pain]]  
*[[Chest pain]]
* [[Headache]]  
*[[Headache]]
* [[Palpitations]]  
*[[Palpitations]]
* [[Flushing]]  
*[[Flushing]]
* Response to [[antidepressants]]  
*Response to [[antidepressants]]
* Fear precedes physical symptoms.  
*Fear precedes physical symptoms.
|
|
* Patients look anxious with tired attitude  
*Patients look anxious with tired attitude
* [[Tachycardia]]
*[[Tachycardia]]
* [[Hypertension]]
*[[Hypertension]]
* [[Sweating]]
*[[Sweating]]
|
|
Laboratory studies that can exclude medical disorders other than [[panic disorder]] include:
Laboratory studies that can exclude medical disorders other than [[panic disorder]] include:
* [[Electrolyte|Serum electrolytes]]  
 
* [[Serum glucose]]
*[[Electrolyte|Serum electrolytes]]
* [[Cardiac enzymes]]
*[[Serum glucose]]
* Urine [[toxicology]] [[Screening (medicine)|screening]]
*[[Cardiac enzymes]]
*Urine [[toxicology]] [[Screening (medicine)|screening]]
|-
|-
|Labile hypertension ([[White coat hypertension]])
| style="background:#DCDCDC;" align="center" |Labile hypertension ([[White coat hypertension]])
|
|
* No history of [[hypertension]]
*No history of [[hypertension]]
|Elevated [[blood pressure]], [[tachycardia]], and may be [[anxiety]] in a clinical setting but not in other settings<sup>[[Chronic hypertension differential diagnosis#cite note-pmid24107724-1|[1]]]</sup>
|Elevated [[blood pressure]], [[tachycardia]], and may be [[anxiety]] in a clinical setting but not in other settings<sup>[[Chronic hypertension differential diagnosis#cite note-pmid24107724-1|[1]]]</sup>
|
|
* Ambulatory blood pressure monitoring and patient self-measurement using a home [[blood pressure]] monitoring device are being increasingly used to differentiate patients with [[white coat hypertension]] from patients with true [[hypertension]].
*Ambulatory [[blood pressure]] monitoring and patient self-measurement using a home [[blood pressure]] monitoring device are being increasingly used to differentiate patients with [[white coat hypertension]] from patients with true [[hypertension]].
|-
|-
|[[Hyperthyroidism]]
| style="background:#DCDCDC;" align="center" |[[Hyperthyroidism]]
|
|
* [[Weight loss]]
*[[Weight loss]]
* Heat intolerance
*Heat intolerance
* [[Tremors]]
*[[Tremors]]
* [[Palpitations]]
*[[Palpitations]]
* [[Anxiety]]
*[[Anxiety]]
* Increased [[bowel]] disturbances
*Increased [[bowel]] disturbances
* [[Shortness of breath]]<ref name="pmid15963064">{{cite journal| author=Iglesias P, Acosta M, Sánchez R, Fernández-Reyes MJ, Mon C, Díez JJ| title=Ambulatory blood pressure monitoring in patients with hyperthyroidism before and after control of thyroid function. | journal=Clin Endocrinol (Oxf) | year= 2005 | volume= 63 | issue= 1 | pages= 66-72 | pmid=15963064 | doi=10.1111/j.1365-2265.2005.02301.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15963064  }}</ref>
*[[Shortness of breath]]<ref name="pmid15963064">{{cite journal| author=Iglesias P, Acosta M, Sánchez R, Fernández-Reyes MJ, Mon C, Díez JJ| title=Ambulatory blood pressure monitoring in patients with hyperthyroidism before and after control of thyroid function. | journal=Clin Endocrinol (Oxf) | year= 2005 | volume= 63 | issue= 1 | pages= 66-72 | pmid=15963064 | doi=10.1111/j.1365-2265.2005.02301.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15963064  }}</ref>
|
|
* [[Goiter|Goiter]]
*[[Goiter|Goiter]]
* Skin [[flushing]]
*Skin [[flushing]]
* [[Proptosis]]
*[[Proptosis]]
* Increased sensitivity of [[beta receptors]] in the heart to [[catecholamines]]<ref name="pmid20454652">{{cite journal| author=Mintz G, Pizzarello R, Klein I| title=Enhanced left ventricular diastolic function in hyperthyroidism: noninvasive assessment and response to treatment. | journal=J Clin Endocrinol Metab | year= 1991 | volume= 73 | issue= 1 | pages= 146-50 | pmid=2045465 | doi=10.1210/jcem-73-1-146 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2045465  }}</ref> due to an effect of [[Thyroid hormone|thyroid hormones]] increase [[cardiac]] work and [[Cardiac Output|output]]
*Increased sensitivity of [[beta receptors]] in the heart to [[catecholamines]]<ref name="pmid20454652">{{cite journal| author=Mintz G, Pizzarello R, Klein I| title=Enhanced left ventricular diastolic function in hyperthyroidism: noninvasive assessment and response to treatment. | journal=J Clin Endocrinol Metab | year= 1991 | volume= 73 | issue= 1 | pages= 146-50 | pmid=2045465 | doi=10.1210/jcem-73-1-146 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2045465  }}</ref> due to an effect of [[Thyroid hormone|thyroid hormones]] increase [[cardiac]] work and [[Cardiac Output|output]]
* [[Systolic hypertension]]<ref name="pmid2045465">{{cite journal| author=Mintz G, Pizzarello R, Klein I| title=Enhanced left ventricular diastolic function in hyperthyroidism: noninvasive assessment and response to treatment. | journal=J Clin Endocrinol Metab | year= 1991 | volume= 73 | issue= 1 | pages= 146-50 | pmid=2045465 | doi=10.1210/jcem-73-1-146 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2045465  }}</ref>
*[[Systolic hypertension]]<ref name="pmid2045465">{{cite journal| author=Mintz G, Pizzarello R, Klein I| title=Enhanced left ventricular diastolic function in hyperthyroidism: noninvasive assessment and response to treatment. | journal=J Clin Endocrinol Metab | year= 1991 | volume= 73 | issue= 1 | pages= 146-50 | pmid=2045465 | doi=10.1210/jcem-73-1-146 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2045465  }}</ref>
|
|
* Low [[thyroid-stimulating hormone]] (TSH)
*Low [[thyroid-stimulating hormone]] ([[Thyroid-stimulating hormone|TSH]])
* High [[Thyroxine|free thyroxine]] (T4) concentration
*High [[Thyroxine|free thyroxine]] ([[T4]]) concentration
* High [[triiodothyronine]] (T3) concentration
*High [[triiodothyronine]] ([[Triiodothyronine|T3]]) concentration
|-
|-
|[[Renal artery stenosis|Renovascular hypertension]]
| style="background:#DCDCDC;" align="center" |[[Renal artery stenosis|Renovascular hypertension]]
|
|
* Common in individuals < 30 years or > 55 years
*Common in individuals < 30 years or > 55 years
* Abrupt onset of [[hypertension]]
*Abrupt onset of [[hypertension]]
* Accelerated [[hypertension]] that was previously well-controlled
*Accelerated [[hypertension]] that was previously well-controlled
* Refractory [[hypertension]] to 3 [[Anti-hypertensive|anti-hypertensive medications]]
*Refractory [[hypertension]] to 3 [[Anti-hypertensive|anti-hypertensive medications]]
* [[Headache]]
*[[Headache]]
* [[Nausea]]
*[[Nausea]]
* [[Subconjunctival hemorrhage]]
*[[Subconjunctival hemorrhage]]
|
|
* [[Bruit]] can be heard over the [[abdomen]]
*[[Bruit]] can be heard over the [[abdomen]]
|
|
* [[Duplex ultrasound|Duplex ultrasonography]] may be used as an initial [[Screening (medicine)|screening]] tool for diagnosis of [[Atherosclerotic disease|atherosclerotic]] [[renal artery stenosis]]
*[[Duplex ultrasound|Duplex ultrasonography]] may be used as an initial [[Screening (medicine)|screening]] tool for diagnosis of [[Atherosclerotic disease|atherosclerotic]] [[renal artery stenosis]]
* [[Ultrasonography]] (might not be very accurate in [[obese]] patients or those with [[intestinal]] gas)<sup>[[Renal artery stenosis ultrasound#cite note-pmid23457117-1|[1]]]</sup>
*[[Ultrasonography]] (might not be very accurate in [[obese]] patients or those with [[intestinal]] gas)<sup>[[Renal artery stenosis ultrasound#cite note-pmid23457117-1|[1]]]</sup>
|-
|-
|[[Stroke]] and [[Lateral medullary syndrome|compression of lateral medulla]] ([[Lateral medullary syndrome]])
| style="background:#DCDCDC;" align="center" |[[Stroke]] and [[Lateral medullary syndrome|compression of lateral medulla]] ([[Lateral medullary syndrome]])
|
|
* Extensive unilateral infarction of the [[brain stem]] in the region of the [[nucleus tractus solitarius]] may result in partial [[Baroreflex|baroreflex dysfunction]], increased sympathetic activity, and neurogenic [[paroxysmal hypertension]].
*Extensive unilateral infarction of the [[brain stem]] in the region of the [[nucleus tractus solitarius]] may result in partial [[Baroreflex|baroreflex dysfunction]], increased sympathetic activity, and [[neurogenic]] [[paroxysmal hypertension]].
* [[Blurred vision]] or [[diplopia]]
*[[Blurred vision]] or [[diplopia]]
* Weakness of [[Bulbar palsy|bulbar muscles]]
*Weakness of [[Bulbar palsy|bulbar muscles]]
* [[Respiratory failure|Respiratory dysfunction]]
*[[Respiratory failure|Respiratory dysfunction]]
* [[Nystagmus]]
*[[Nystagmus]]
* [[Dizziness]]
*[[Dizziness]]
|
|
* Difficulty sitting upright without support
*Difficulty sitting upright without support
* [[Hypotonia]] of the ipsilateral arm
*[[Hypotonia]] of the ipsilateral arm
* Ipsilateral decreased pain and temperature sensation in the face
*Ipsilateral decreased pain and temperature sensation in the face
* The [[corneal reflex]] is usually reduced in the [[ipsilateral]] eye
*The [[corneal reflex]] is usually reduced in the [[ipsilateral]] eye
* Contralateral loss of pain and thermal sensation involving the body and limbs
*Contralateral loss of [[pain]] and thermal sensation involving the body and limbs
|
|
* [[Computed tomography|CT]] shows mass compressing [[Lateral medullary syndrome|lateral medulla]] or infarction in the same area
*[[Computed tomography|CT]] shows mass compressing [[Lateral medullary syndrome|lateral medulla]] or infarction in the same area
|-
|-
|[[Seizures]]  
| style="background:#DCDCDC;" align="center" |[[Seizures]]
|According to type; it may be focal or generalized, clinical or subclinical:<ref name="pmid2045465" />
|According to type; it may be focal or generalized, clinical or subclinical:<ref name="pmid2045465" />
* [[Tonic-clonic seizure]]:
 
** Repetitive twitches of arm and legs
*[[Tonic-clonic seizure]]:
** Tongue bitting
**Repetitive twitches of arm and legs
** [[Loss of consciousness]]
**[[Tongue]] bitting
** Symptoms occur suddenly and may persist
**[[Loss of consciousness]]
** [[Muscle]] tension or tightening that causes twisting of the body, head, arms, or legs
**Symptoms occur suddenly and may persist
** [[Amnesia]]
**[[Muscle]] tension or tightening that causes twisting of the body, head, arms, or legs
** Mood changes (fear, panic, or laughter)
**[[Amnesia]]
** Change in sensation of the skin over the arm, leg, or trunk
**Mood changes (fear, panic, or laughter)
** Vision changes and light flashes
**Change in sensation of the skin over the arm, leg, or trunk
** [[Hallucination|Hallucinations]]
**Vision changes and light flashes
** Tasting a bitter or metallic flavor
**[[Hallucination|Hallucinations]]
* [[Complex partial seizure]]:
**Tasting a bitter or metallic flavor
** Confused or dazed and
*[[Complex partial seizure]]:
** Not be able to respond to questions or direction
**Confused or dazed and
* [[Absence seizure]]:
**Not be able to respond to questions or direction
** Rapid blinking  
*[[Absence seizure]]:
** Few seconds of staring into space
**Rapid blinking
**Few seconds of staring into space
  |
  |
* Physical examination is important when [[central nervous system infection]] or hemorrhage are diagnostic possibilities
*Physical examination is important when [[central nervous system infection]] or hemorrhage are diagnostic possibilities


* A tongue bite or laceration in [[Tonic-clonic seizure|generalized tonic-clonic seizure]]<ref name="pmid23041172">{{cite journal|author=Brigo F, Storti M, Lochner P, Tezzon F, Fiaschi A, Bongiovanni LG et al.|title=Tongue biting in epileptic seizures and psychogenic events: an evidence-based perspective.|journal=Epilepsy Behav|year=2012|volume=25|issue=2|pages=251-5|pmid=23041172|doi=10.1016/j.yebeh.2012.06.020|pmc=|url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23041172}}</ref>
*A [[tongue]] bite or laceration in [[Tonic-clonic seizure|generalized tonic-clonic seizure]]<ref name="pmid23041172">{{cite journal|author=Brigo F, Storti M, Lochner P, Tezzon F, Fiaschi A, Bongiovanni LG et al.|title=Tongue biting in epileptic seizures and psychogenic events: an evidence-based perspective.|journal=Epilepsy Behav|year=2012|volume=25|issue=2|pages=251-5|pmid=23041172|doi=10.1016/j.yebeh.2012.06.020|pmc=|url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23041172}}</ref>
|
|
* Abnormal [[electroencephalography]]: a positive test without a clinical presentation is called a [[Subclinical seizure|sub-clinical seizure]].<ref name="pmid21205698">{{cite journal|author=Fountain NB, Van Ness PC, Swain-Eng R, Tonn S, Bever CT, American Academy of Neurology Epilepsy Measure Development Panel and the American Medical Association-Convened Physician Consortium for Performance Improvement Independent Measure Development Process|title=Quality improvement in neurology: AAN epilepsy quality measures: Report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology.|journal=Neurology|year=2011|volume=76|issue=1|pages=94-9|pmid=21205698|doi=10.1212/WNL.0b013e318203e9d1|pmc=|url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21205698}}</ref>
*Abnormal [[electroencephalography]]: a positive test without a clinical presentation is called a [[Subclinical seizure|sub-clinical seizure]].<ref name="pmid21205698">{{cite journal|author=Fountain NB, Van Ness PC, Swain-Eng R, Tonn S, Bever CT, American Academy of Neurology Epilepsy Measure Development Panel and the American Medical Association-Convened Physician Consortium for Performance Improvement Independent Measure Development Process|title=Quality improvement in neurology: AAN epilepsy quality measures: Report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology.|journal=Neurology|year=2011|volume=76|issue=1|pages=94-9|pmid=21205698|doi=10.1212/WNL.0b013e318203e9d1|pmc=|url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21205698}}</ref>
* [[Lumbar puncture]] is useful to exclude acute [[central nervous system infections]].
*[[Lumbar puncture]] is useful to exclude acute [[central nervous system infections]].
* A neuroimaging study should be performed in all adults with a first seizure to evaluate structural brain abnormalities. [[Magnetic resonance imaging]] is preferred over [[computed tomography]].
*A neuro-imaging study should be performed in all adults with a first [[seizure]] to evaluate structural [[brain]] abnormalities. [[Magnetic resonance imaging]] is preferred over [[computed tomography]].
|-
|-
|[[Carcinoid syndrome]]
| style="background:#DCDCDC;" align="center" |[[Carcinoid syndrome]]
|[[Hypertensive crisis]] occurs with [[malignant carcinoid syndrome]]<ref name="pmid7969229">{{cite journal| author=Warner RR, Mani S, Profeta J, Grunstein E| title=Octreotide treatment of carcinoid hypertensive crisis. | journal=Mt Sinai J Med | year= 1994 | volume= 61 | issue= 4 | pages= 349-55 | pmid=7969229 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7969229  }}</ref>. Symptoms include:
|[[Hypertensive crisis]] occurs with [[malignant carcinoid syndrome]]<ref name="pmid7969229">{{cite journal| author=Warner RR, Mani S, Profeta J, Grunstein E| title=Octreotide treatment of carcinoid hypertensive crisis. | journal=Mt Sinai J Med | year= 1994 | volume= 61 | issue= 4 | pages= 349-55 | pmid=7969229 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7969229  }}</ref>.  
* Severe [[chest]] pain
Symptoms include:
* Severe [[headache]]
 
* [[Confusion]] and [[blurred vision]]
*Severe [[chest]] pain
* [[Nausea and vomiting]]
*Severe [[headache]]
* Severe [[anxiety]]
*[[Confusion]] and [[blurred vision]]
* [[Shortness of breath]]
*[[Nausea and vomiting]]
* [[Seizures]]
*Severe [[anxiety]]
* Unresponsiveness
*[[Shortness of breath]]
*[[Seizures]]
*Unresponsiveness
|
|
* [[Cutaneous]] [[flushing]]
*[[Cutaneous]] [[flushing]]
* [[Venous]] [[telangiectasia]]
*[[Venous]] [[telangiectasia]]
* [[Diarrhea]]
*[[Diarrhea]]
* [[Bronchospasm]]
*[[Bronchospasm]]
* [[Valvular heart disease|Cardiac valvular lesions]] ([[Tricuspid regurgitation|tricuspid incompetence]])
*[[Valvular heart disease|Cardiac valvular lesions]] ([[Tricuspid regurgitation|tricuspid incompetence]])
|
|
* High urinary excretion of [[5-HIAA]]<ref name="pmid3227292">{{cite journal| author=Sjöblom SM| title=Clinical presentation and prognosis of gastrointestinal carcinoid tumours. | journal=Scand J Gastroenterol | year= 1988 | volume= 23 | issue= 7 | pages= 779-87 | pmid=3227292 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3227292  }}</ref>
*High urinary excretion of [[5-HIAA]]<ref name="pmid3227292">{{cite journal| author=Sjöblom SM| title=Clinical presentation and prognosis of gastrointestinal carcinoid tumours. | journal=Scand J Gastroenterol | year= 1988 | volume= 23 | issue= 7 | pages= 779-87 | pmid=3227292 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3227292  }}</ref>
* High  urinary excretion of [[serotonin]]<ref name="pmid2421946">{{cite journal| author=Feldman JM| title=Urinary serotonin in the diagnosis of carcinoid tumors. | journal=Clin Chem | year= 1986 | volume= 32 | issue= 5 | pages= 840-4 | pmid=2421946 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2421946  }}</ref>
*High  urinary excretion of [[serotonin]]<ref name="pmid2421946">{{cite journal| author=Feldman JM| title=Urinary serotonin in the diagnosis of carcinoid tumors. | journal=Clin Chem | year= 1986 | volume= 32 | issue= 5 | pages= 840-4 | pmid=2421946 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2421946  }}</ref>
* High [[chromogranin]] concentration[[Chromogranin|(Chromogranin]](A, B, and C) are proteins that are stored and released with [[peptides]] and [[amines]] in a variety of [[Neuroendocrine cells|neuroendocrine tissues]])<ref name="pmid2316306">{{cite journal| author=Eriksson B, Arnberg H, Oberg K, Hellman U, Lundqvist G, Wernstedt C et al.| title=A polyclonal antiserum against chromogranin A and B--a new sensitive marker for neuroendocrine tumours. | journal=Acta Endocrinol (Copenh) | year= 1990 | volume= 122 | issue= 2 | pages= 145-55 | pmid=2316306 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2316306  }}</ref>
*High [[chromogranin]] concentration[[Chromogranin|(Chromogranin]](A, B, and C) are proteins that are stored and released with [[peptides]] and [[amines]] in a variety of [[Neuroendocrine cells|neuroendocrine tissues]])<ref name="pmid2316306">{{cite journal| author=Eriksson B, Arnberg H, Oberg K, Hellman U, Lundqvist G, Wernstedt C et al.| title=A polyclonal antiserum against chromogranin A and B--a new sensitive marker for neuroendocrine tumours. | journal=Acta Endocrinol (Copenh) | year= 1990 | volume= 122 | issue= 2 | pages= 145-55 | pmid=2316306 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2316306  }}</ref>


* [[Computed tomography|CT]] is recommended for evaluation of all patients with [[Carcinoid syndrome|carcinoid tumors]].<ref name="pmid19077417">{{cite journal| author=Sundin A, Vullierme MP, Kaltsas G, Plöckinger U, Mallorca Consensus Conference participants. European Neuroendocrine Tumor Society| title=ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. | journal=Neuroendocrinology | year= 2009 | volume= 90 | issue= 2 | pages= 167-83 | pmid=19077417 | doi=10.1159/000184855 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19077417  }}</ref>
*[[Computed tomography|CT]] is recommended for evaluation of all patients with [[Carcinoid syndrome|carcinoid tumors]].<ref name="pmid19077417">{{cite journal| author=Sundin A, Vullierme MP, Kaltsas G, Plöckinger U, Mallorca Consensus Conference participants. European Neuroendocrine Tumor Society| title=ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. | journal=Neuroendocrinology | year= 2009 | volume= 90 | issue= 2 | pages= 167-83 | pmid=19077417 | doi=10.1159/000184855 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19077417  }}</ref>
|-
|-
|[[Migraine headaches]]
| style="background:#DCDCDC;" align="center" |[[Migraine headaches]]
|
|
* '''Prodrome:'''
*'''Prodrome:'''
** Occurs hours or days before a [[headache]]
**Occurs hours or days before a [[headache]]


* '''[[Aura (symptom)|Aura]]'''  
*'''[[Aura (symptom)|Aura]]'''  
** Immediately precedes the [[headache]]  
**Immediately precedes the [[headache]]


* Pain phase  
*Pain phase  
** Also known as [[headache]] phase  
**Also known as [[headache]] phase


* Postdrome phase'''<ref name="pmid15447695">{{cite journal| author=Kelman L| title=The premonitory symptoms (prodrome): a tertiary care study of 893 migraineurs. | journal=Headache | year= 2004 | volume= 44 | issue= 9 | pages= 865-72 | pmid=15447695 | doi=10.1111/j.1526-4610.2004.04168.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15447695  }}</ref>'''
*Postdrome phase'''<ref name="pmid15447695">{{cite journal| author=Kelman L| title=The premonitory symptoms (prodrome): a tertiary care study of 893 migraineurs. | journal=Headache | year= 2004 | volume= 44 | issue= 9 | pages= 865-72 | pmid=15447695 | doi=10.1111/j.1526-4610.2004.04168.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15447695  }}</ref>'''
|
|
* [[Red eye|Conjunctival injection]]
*[[Red eye|Conjunctival injection]]


* [[Horner's syndrome]]<sup>[[Migraine physical examination#cite note-1|[1]]]</sup> 
*[[Horner's syndrome]]<sup>[[Migraine physical examination#cite note-1|[1]]]</sup> 
* [[Adie's pupil]] <sup>[[Migraine physical examination#cite note-2|[2]]]</sup> 
*[[Adie's pupil]] <sup>[[Migraine physical examination#cite note-2|[2]]]</sup> 


* [[Cranial]]/ [[Cervical spine|cervical]] [[muscle]] [[tenderness]] 
*[[Cranial]]/ [[Cervical spine|cervical]] [[muscle]] [[tenderness]] 
* [[Bruit]] at [[neck]] and [[head]] for clinical signs of [[Cerebral arteriovenous malformation|an arteriovenous malformation]]
*[[Bruit]] at [[neck]] and [[head]] for clinical signs of [[Cerebral arteriovenous malformation|an arteriovenous malformation]]
* [[Photosensitivity]]
*[[Photosensitivity]]
|'''[[CT]] is indicated in patients with:'''<sup>[[Migraine CT#cite note-1|[1]]]</sup><sup>[[Migraine CT#cite note-pmid24400971-2|[2]]]</sup>
|'''[[CT]] is indicated in patients with:'''<sup>[[Migraine CT#cite note-1|[1]]]</sup><sup>[[Migraine CT#cite note-pmid24400971-2|[2]]]</sup>
* Abnormal [[physical examination]]:
 
** Increase of [[headache]]'s frequency
*Abnormal [[physical examination]]:
** Poor [[coordination]]
**Increase of [[headache]]'s frequency
** [[Focal neurologic signs]]
**Poor [[coordination]]
** [[Headache]]<nowiki/>s awakening the patient at nigt<sup>[[Migraine CT#cite note-3|[3]]][[Migraine CT#cite note-4|[4]]]</sup>
**[[Focal neurologic signs]]
* Atypical [[aura]]
**[[Headache]]<nowiki/>s awakening the patient at night<sup>[[Migraine CT#cite note-3|[3]]][[Migraine CT#cite note-4|[4]]]</sup>
* Sudden onset
*Atypical [[aura]]
* Lasting more than 1 hour
*Sudden onset
* Always on the same side  
*Lasting more than 1 hour
* With or without [[visual]] symptoms
*Always on the same side
* [[Migraine]] attacks that begin after 50 years of age
*With or without [[visual]] symptoms
*[[Migraine]] attacks that begin after 50 years of age
 
'''[[CT]] is not indicated in:'''
'''[[CT]] is not indicated in:'''
* Patients with a diagnosis of a migraine in accordance with the [[Migraine classification|criteria for migraine]]
 
* Differentiating a migraine from other primary [[headaches]]
*Patients with a diagnosis of a migraine in accordance with the [[Migraine classification|criteria for migraine]]
*Differentiating a migraine from other primary [[headaches]]
|-
|-
|Drugs
| style="background:#DCDCDC;" align="center" |Drugs
|[[Sympathomimetic drug|Sympathomimetic drugs]] that can induce symptoms simulating pheochromocytoma include:
|[[Sympathomimetic drug|Sympathomimetic drugs]] that can induce symptoms simulating pheochromocytoma include:
* High-dose [[phenylpropanolamine]]
 
* [[Cocaine]]
*High-dose [[phenylpropanolamine]]
* [[Amphetamine|Amphetamines]]
*[[Cocaine]]
* Lysergic acid diethylamide ([[Lysergic Acid Diethylamide|LSD]])
*[[Amphetamine|Amphetamines]]
* Phenylcyclidine (PCP)<ref name="pmid11358774">{{cite journal| author=Krentz AJ, Mikhail S, Cantrell P, Hill GM| title=Drug Points: Pseudophaeochromocytoma syndrome associated with clozapine. | journal=BMJ | year= 2001 | volume= 322 | issue= 7296 | pages= 1213 | pmid=11358774 | doi= | pmc=31620 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11358774  }}</ref>  
*Lysergic acid diethylamide ([[Lysergic Acid Diethylamide|LSD]])
* Combination of a [[Monoamine oxidase inhibitor|monoamine oxidase (MAO) inhibitor]] and ingestion of [[Tyramine|tyramine-containing]] foods.<ref name="pmid3980057">{{cite journal| author=Kuchel O| title=Pseudopheochromocytoma. | journal=Hypertension | year= 1985 | volume= 7 | issue= 1 | pages= 151-8 | pmid=3980057 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3980057  }}</ref>
*Phenylcyclidine (PCP)<ref name="pmid11358774">{{cite journal| author=Krentz AJ, Mikhail S, Cantrell P, Hill GM| title=Drug Points: Pseudophaeochromocytoma syndrome associated with clozapine. | journal=BMJ | year= 2001 | volume= 322 | issue= 7296 | pages= 1213 | pmid=11358774 | doi= | pmc=31620 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11358774  }}</ref>
*Combination of a [[Monoamine oxidase inhibitor|monoamine oxidase (MAO) inhibitor]] and ingestion of [[Tyramine|tyramine-containing]] foods.<ref name="pmid3980057">{{cite journal| author=Kuchel O| title=Pseudopheochromocytoma. | journal=Hypertension | year= 1985 | volume= 7 | issue= 1 | pages= 151-8 | pmid=3980057 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3980057  }}</ref>
|
|
* Disturbed [[consciousness]]
*Disturbed [[consciousness]]
* [[Nasal septum]] perforation in [[cocaine addiction]]
*[[Nasal septum]] perforation in [[cocaine addiction]]
* Needle marks on the [[skin]]
*Needle marks on the [[skin]]
* History of [[antidepressants|antidepressant]]<nowiki/>intake
*History of [[antidepressants|antidepressant]]<nowiki/>intake
|
|
* [[Urine]] [[Toxicology screen|toxicology screening]]
*[[Urine]] [[Toxicology screen|toxicology screening]]
|-
|-
|[[Baroreflex|Baroreflex failure]]<ref name="pmid8413455">{{cite journal| author=Robertson D, Hollister AS, Biaggioni I, Netterville JL, Mosqueda-Garcia R, Robertson RM| title=The diagnosis and treatment of baroreflex failure. | journal=N Engl J Med | year= 1993 | volume= 329 | issue= 20 | pages= 1449-55 | pmid=8413455 | doi=10.1056/NEJM199311113292003 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8413455  }}</ref>
| style="background:#DCDCDC;" align="center" |[[Baroreflex|Baroreflex failure]]<ref name="pmid8413455">{{cite journal| author=Robertson D, Hollister AS, Biaggioni I, Netterville JL, Mosqueda-Garcia R, Robertson RM| title=The diagnosis and treatment of baroreflex failure. | journal=N Engl J Med | year= 1993 | volume= 329 | issue= 20 | pages= 1449-55 | pmid=8413455 | doi=10.1056/NEJM199311113292003 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8413455  }}</ref>
|
|
* Marked and frequent fluctuations in [[blood pressure]],<ref name="pmid183225442">{{cite journal| author=Zar T, Peixoto AJ| title=Paroxysmal hypertension due to baroreflex failure. | journal=Kidney Int | year= 2008 | volume= 74 | issue= 1 | pages= 126-31 | pmid=18322544 | doi=10.1038/ki.2008.30 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18322544  }}</ref> with both high and low readings.  
*Marked and frequent fluctuations in [[blood pressure]],<ref name="pmid183225442">{{cite journal| author=Zar T, Peixoto AJ| title=Paroxysmal hypertension due to baroreflex failure. | journal=Kidney Int | year= 2008 | volume= 74 | issue= 1 | pages= 126-31 | pmid=18322544 | doi=10.1038/ki.2008.30 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18322544  }}</ref> with both high and low readings.
* It is caused by hypofunctioning of [[Baroreflex|baroreflexes]] that normally buffer [[blood pressure]] fluctuations.  
*It is caused by hypofunctioning of [[Baroreflex|baroreflexes]] that normally buffer [[blood pressure]] fluctuations.
* The disorder is usually a result of injury to [[Baroreceptors|carotid baroreceptors]], with most patients reporting a history of neck [[irradiation]] or [[surgery]].<ref name="pmid183225442" />  
*The disorder is usually a result of injury to [[Baroreceptors|carotid baroreceptors]], with most patients reporting a history of neck [[irradiation]] or [[surgery]].<ref name="pmid183225442" />
* History of changes of heart rate during normal daily activities  
*History of changes of heart rate during normal daily activities
|
|
* Increase in blood pressure with standing.
*Increase in blood pressure with standing.
* Profound [[orthostatic hypotension]] in the absence of an adequate heart rate increase. The [[hypotension]] is immediately reversible in the [[Supine position|supine position.]]
*Profound [[orthostatic hypotension]] in the absence of an adequate heart rate increase. The [[hypotension]] is immediately reversible in the [[Supine position|supine position.]]


* Determination of [[respiratory sinus arrhythmia]], [[Valsalva maneuver|a Valsalva maneuver,]] and cold-pressor and handgrip testing, can be helpful to diagnose it.  
*Determination of [[respiratory sinus arrhythmia]], [[Valsalva maneuver|a Valsalva maneuver,]] and cold-pressor and handgrip testing, can be helpful to diagnose it.


* Baroreflex failure patients show a normal or even an increased pressor response to cold-pressor and handgrip testing. These responses are attenuated in patients with autonomic failure.
*Baroreflex failure patients show a normal or even an increased pressor response to cold-pressor and handgrip testing. These responses are attenuated in patients with autonomic failure.


* Twenty-four–hour [[blood pressure]] monitor can be useful to demonstrate the large [[blood pressure]] fluctuations and the tracking of [[blood pressure]] and [[heart rate]].
*Twenty-four–hour [[blood pressure]] monitor can be useful to demonstrate the large [[blood pressure]] fluctuations and the tracking of [[blood pressure]] and [[heart rate]].
|
|
* Neck [[Computed tomography|CT]] scan
*Neck [[Computed tomography|CT]] scan
|}
|}



Latest revision as of 02:58, 10 May 2021

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohammed Abdelwahed M.D[2]

Overview

Adrenal incidentaloma must be differentiated from other diseases that cause adrenal masses such as adrenal adenoma, adrenocortical carcinoma, Cushing's syndrome, pheochromocytoma, metastasis, and other causes of bilateral adrenal masses.

Differentiating different causese of Incidentaloma

Differential Diagnosis Clinical picture Imagings Laboratory tests
Adrenal adenoma
  • Round and homogeneous density, smooth contour and sharp margination
  • Diameter less than 4 cm, unilateral location
  • Low unenhanced CT attenuation values (<10 HU)
  • Rapid contrast medium washout (10 minutes after administration of contrast, an absolute contrast medium washout of more than 50 percent)
  • Isointensity with liver on both T1 and T2 weighted MRI sequences
  • Chemical shift: evidence of lipid on MRI
Adrenocortical carcinoma
  • Irregular shape
  • Inhomogeneous density because of central areas of low attenuation due to tumor necrosis
  • Tumor calcification
  • Diameter usually > 4 cm
  • Unilateral location
  • High unenhanced CT attenuation values (>20 HU)
  • Inhomogeneous enhancement on CT with intravenous contrast
  • Delay in contrast medium washout (10 minutes after administration of contrast, an absolute contrast medium washout of less than 50 percent)
  • Hypointensity compared with liver on T1 weighted MRI and high to intermediate signal intensity on T2 weighted MRI
  • High standardized uptake value (SUV) on FDG-PET-CT study
  • Evidence of local invasion or metastases
Cushing's syndrome
  • Imaging may show mass if presents
Pheochromocytoma
  • Increased attenuation on nonenhanced CT ( > 20 HU)
  • Increased mass vascularity
  • Delay in contrast medium washout (10 minutes after administration of contrast, an absolute contrast medium washout of less than 50 percent)
  • High signal intensity on T2 weighted MRI
  • Cystic and hemorrhagic changes
  • Variable size and may be bilateral
Adrenal metastasis
    • Irregular shape and inhomogeneous nature
    • Tendency to be bilateral
    • High unenhanced CT attenuation values ( > 20 HU) and enhancement with intravenous contrast on CT
    • Delay in contrast medium washout (10 minutes after administration of contrast, an absolute contrast medium washout of less than 50 percent)
    • Iso-intensity or slightly less intense than the liver on T1 weighted MRI and high to intermediate signal intensity on T2 weighted MRI (representing an increased water content)
    • Elevated standardized uptake value on FDG-PET scan

Differential diagnosis of Cushing's disease from other diseases

The table below summarizes the findings that differentiate Cushing's disease from other conditions that may cause hypertension, hyperandrogenism, and obesity. Facial plethora, skin changes, osteoporosis, nephrolithiasis and neuropsychiatric conditions should raise the concern for Cushing's syndrome.[1][2][3][4]

Conditions Causes Associated features Diagnostic approach
Cushing's syndrome
Pseudo-Cushing's syndrome
Metabolic syndrome X

Differentiating pheochromocytoma from other diseases

Pheochromocytoma must be differentiated from other causes of paroxysmal hypertension. The differentials include:

Disease Symptoms Signs Investigations
Pheochromocytoma The symptoms of a pheochromocytoma are those of sympathetic nervous systemhyperactivity and include:[1]
Pseudopheochromocytoma (idiopathic)[5][6][7][8] Paroxysmal activation of the sympathetic system causing:
Panic attacks

Laboratory studies that can exclude medical disorders other than panic disorder include:

Labile hypertension (White coat hypertension) Elevated blood pressure, tachycardia, and may be anxiety in a clinical setting but not in other settings[1]
Hyperthyroidism
Renovascular hypertension
Stroke and compression of lateral medulla (Lateral medullary syndrome)
  • Difficulty sitting upright without support
  • Hypotonia of the ipsilateral arm
  • Ipsilateral decreased pain and temperature sensation in the face
  • The corneal reflex is usually reduced in the ipsilateral eye
  • Contralateral loss of pain and thermal sensation involving the body and limbs
Seizures According to type; it may be focal or generalized, clinical or subclinical:[11]
  • Tonic-clonic seizure:
    • Repetitive twitches of arm and legs
    • Tongue bitting
    • Loss of consciousness
    • Symptoms occur suddenly and may persist
    • Muscle tension or tightening that causes twisting of the body, head, arms, or legs
    • Amnesia
    • Mood changes (fear, panic, or laughter)
    • Change in sensation of the skin over the arm, leg, or trunk
    • Vision changes and light flashes
    • Hallucinations
    • Tasting a bitter or metallic flavor
  • Complex partial seizure:
    • Confused or dazed and
    • Not be able to respond to questions or direction
  • Absence seizure:
    • Rapid blinking
    • Few seconds of staring into space
Carcinoid syndrome Hypertensive crisis occurs with malignant carcinoid syndrome[14].

Symptoms include:

Migraine headaches
  • Prodrome:
  • Pain phase
CT is indicated in patients with:[1][2]

CT is not indicated in:

Drugs Sympathomimetic drugs that can induce symptoms simulating pheochromocytoma include:
Baroreflex failure[22]
  • Baroreflex failure patients show a normal or even an increased pressor response to cold-pressor and handgrip testing. These responses are attenuated in patients with autonomic failure.
  • Neck CT scan

References

  1. Boscaro M, Barzon L, Fallo F, Sonino N (2001). "Cushing's syndrome". Lancet. 357 (9258): 783–91. doi:10.1016/S0140-6736(00)04172-6. PMID 11253984.
  2. Findling JW, Raff H (2001). "Diagnosis and differential diagnosis of Cushing's syndrome". Endocrinol. Metab. Clin. North Am. 30 (3): 729–47. PMID 11571938.
  3. Newell-Price J, Trainer P, Besser M, Grossman A (1998). "The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states". Endocr. Rev. 19 (5): 647–72. doi:10.1210/edrv.19.5.0346. PMID 9793762.
  4. "How Is Metabolic Syndrome Diagnosed? - NHLBI, NIH".
  5. Mann SJ (1999). "Severe paroxysmal hypertension (pseudopheochromocytoma): understanding the cause and treatment". Arch Intern Med. 159 (7): 670–4. PMID 10218745.
  6. Mann SJ (1999). "Severe paroxysmal hypertension (pseudopheochromocytoma): understanding the cause and treatment". Arch Intern Med. 159 (7): 670–4. PMID 10218745.
  7. Mann SJ (1996). "Severe paroxysmal hypertension. An automatic syndrome and its relationship to repressed emotions". Psychosomatics. 37 (5): 444–50. doi:10.1016/S0033-3182(96)71532-3. PMID 8824124.
  8. Sharabi Y, Goldstein DS, Bentho O, Saleem A, Pechnik S, Geraci MF; et al. (2007). "Sympathoadrenal function in patients with paroxysmal hypertension: pseudopheochromocytoma". J Hypertens. 25 (11): 2286–95. doi:10.1097/HJH.0b013e3282ef5fac. PMID 17921824.
  9. Iglesias P, Acosta M, Sánchez R, Fernández-Reyes MJ, Mon C, Díez JJ (2005). "Ambulatory blood pressure monitoring in patients with hyperthyroidism before and after control of thyroid function". Clin Endocrinol (Oxf). 63 (1): 66–72. doi:10.1111/j.1365-2265.2005.02301.x. PMID 15963064.
  10. Mintz G, Pizzarello R, Klein I (1991). "Enhanced left ventricular diastolic function in hyperthyroidism: noninvasive assessment and response to treatment". J Clin Endocrinol Metab. 73 (1): 146–50. doi:10.1210/jcem-73-1-146. PMID 2045465.
  11. 11.0 11.1 Mintz G, Pizzarello R, Klein I (1991). "Enhanced left ventricular diastolic function in hyperthyroidism: noninvasive assessment and response to treatment". J Clin Endocrinol Metab. 73 (1): 146–50. doi:10.1210/jcem-73-1-146. PMID 2045465.
  12. Brigo F, Storti M, Lochner P, Tezzon F, Fiaschi A, Bongiovanni LG; et al. (2012). "Tongue biting in epileptic seizures and psychogenic events: an evidence-based perspective". Epilepsy Behav. 25 (2): 251–5. doi:10.1016/j.yebeh.2012.06.020. PMID 23041172.
  13. Fountain NB, Van Ness PC, Swain-Eng R, Tonn S, Bever CT, American Academy of Neurology Epilepsy Measure Development Panel and the American Medical Association-Convened Physician Consortium for Performance Improvement Independent Measure Development Process (2011). "Quality improvement in neurology: AAN epilepsy quality measures: Report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology". Neurology. 76 (1): 94–9. doi:10.1212/WNL.0b013e318203e9d1. PMID 21205698.
  14. Warner RR, Mani S, Profeta J, Grunstein E (1994). "Octreotide treatment of carcinoid hypertensive crisis". Mt Sinai J Med. 61 (4): 349–55. PMID 7969229.
  15. Sjöblom SM (1988). "Clinical presentation and prognosis of gastrointestinal carcinoid tumours". Scand J Gastroenterol. 23 (7): 779–87. PMID 3227292.
  16. Feldman JM (1986). "Urinary serotonin in the diagnosis of carcinoid tumors". Clin Chem. 32 (5): 840–4. PMID 2421946.
  17. Eriksson B, Arnberg H, Oberg K, Hellman U, Lundqvist G, Wernstedt C; et al. (1990). "A polyclonal antiserum against chromogranin A and B--a new sensitive marker for neuroendocrine tumours". Acta Endocrinol (Copenh). 122 (2): 145–55. PMID 2316306.
  18. Sundin A, Vullierme MP, Kaltsas G, Plöckinger U, Mallorca Consensus Conference participants. European Neuroendocrine Tumor Society (2009). "ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations". Neuroendocrinology. 90 (2): 167–83. doi:10.1159/000184855. PMID 19077417.
  19. Kelman L (2004). "The premonitory symptoms (prodrome): a tertiary care study of 893 migraineurs". Headache. 44 (9): 865–72. doi:10.1111/j.1526-4610.2004.04168.x. PMID 15447695.
  20. Krentz AJ, Mikhail S, Cantrell P, Hill GM (2001). "Drug Points: Pseudophaeochromocytoma syndrome associated with clozapine". BMJ. 322 (7296): 1213. PMC 31620. PMID 11358774.
  21. Kuchel O (1985). "Pseudopheochromocytoma". Hypertension. 7 (1): 151–8. PMID 3980057.
  22. Robertson D, Hollister AS, Biaggioni I, Netterville JL, Mosqueda-Garcia R, Robertson RM (1993). "The diagnosis and treatment of baroreflex failure". N Engl J Med. 329 (20): 1449–55. doi:10.1056/NEJM199311113292003. PMID 8413455.
  23. 23.0 23.1 Zar T, Peixoto AJ (2008). "Paroxysmal hypertension due to baroreflex failure". Kidney Int. 74 (1): 126–31. doi:10.1038/ki.2008.30. PMID 18322544.

Template:WH Template:WS